• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将普通医疗保健融入私立社区精神病学实践。

Integrating general health care in private community psychiatry practice.

作者信息

Goff Donald C

机构信息

Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA.

出版信息

J Clin Psychiatry. 2007;68 Suppl 4:49-54.

PMID:17539701
Abstract

Persons with serious mental illness represent a special at-risk population, with elevated medical comorbidity and mortality rates, mainly due to cardiovascular disease. For this reason, the treatment plan for patients with mental illness must include the assessment of medical risk factors, beginning at the time of the initial psychiatric evaluation. Follow-up assessments should proceed as recommended by the Expert Consensus Development Panel convened by the American Diabetes Association, the American Psychiatric Association, and other relevant specialty organizations. Because the various second-generation antipsychotics (SGAs) have unique side effect profiles with respect to cardiometabolic risk factors, such as weight gain and dyslipidemia, the selection of an SGA always should weigh efficacy versus potential risks. Prior to initiating antipsychotic therapy, the psychiatrist should not only explain to the patient the risks of the medication and alternative treatments, but also address preventive strategies and the importance of monitoring. To help evaluate the patient's response and manage SGA-related adverse effects, the psychiatrist should spend considerable time in contact with the patient, the patient's family and/or caregivers (as appropriate), and the patient's primary care physician. To enhance overall patient care, the psychiatrist in private practice should implement procedures to ensure adequate patient education and address overall health monitoring. Furthermore, the psychiatrist must serve as a patient advocate, actively working to foster communication with medical colleagues, especially primary care practitioners, and identify resources in the community that facilitate preventive health care.

摘要

患有严重精神疾病的人群是一个特殊的高危群体,其合并症和死亡率较高,主要原因是心血管疾病。因此,精神疾病患者的治疗计划必须包括对医疗风险因素的评估,从初次精神科评估时就开始。后续评估应按照美国糖尿病协会、美国精神科协会及其他相关专业组织召集的专家共识发展小组的建议进行。由于各种第二代抗精神病药物(SGA)在心脏代谢风险因素方面,如体重增加和血脂异常,具有独特的副作用特征,所以选择SGA时应始终权衡疗效与潜在风险。在开始抗精神病药物治疗之前,精神科医生不仅应向患者解释药物风险和替代治疗方法,还应说明预防策略以及监测的重要性。为了帮助评估患者的反应并管理与SGA相关的不良反应,精神科医生应花费大量时间与患者、患者家属和/或护理人员(视情况而定)以及患者的初级保健医生进行沟通。为了加强对患者的整体护理,私人执业的精神科医生应实施相关程序,以确保对患者进行充分的教育并进行全面的健康监测。此外,精神科医生必须成为患者的倡导者,积极促进与医疗同事,尤其是初级保健医生的沟通,并在社区中寻找有助于预防性医疗保健的资源。

相似文献

1
Integrating general health care in private community psychiatry practice.将普通医疗保健融入私立社区精神病学实践。
J Clin Psychiatry. 2007;68 Suppl 4:49-54.
2
[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].[制定重症精神疾病患者身体健康检查指南]
Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9.
3
Implementation of monitoring and management guidelines for second-generation antipsychotics.第二代抗精神病药物监测与管理指南的实施
J Clin Psychiatry. 2007;68 Suppl 4:14-8.
4
Primary care issues in patients with mental illness.患有精神疾病患者的初级保健问题。
Am Fam Physician. 2008 Aug 1;78(3):355-62.
5
Schizophrenia and comorbid metabolic disorders.精神分裂症与共病代谢紊乱。
J Clin Psychiatry. 2005;66 Suppl 6:11-20.
6
Bridging the gap between mental and physical health: a multidisciplinary approach.弥合心理健康与身体健康之间的差距:一种多学科方法。
J Clin Psychiatry. 2007;68 Suppl 4:26-33.
7
Metabolic syndrome and mental illness.代谢综合征与精神疾病。
Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7.
8
Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.精神疾病中的代谢和内分泌紊乱:合理使用非典型抗精神病药物的多学科方法。
CNS Spectr. 2005 Oct;10(10):suppl14 1-15.
9
[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].[法国13家精神病医院抗精神病药物的处方模式]
Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7.
10
Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.精神分裂症的长期健康考量:代谢影响及腹部肥胖的作用。
Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S142-8. doi: 10.1016/j.euroneuro.2006.06.005. Epub 2006 Jul 24.

引用本文的文献

1
Staff Perceptions of Barriers and Facilitators to Implementation of Behavioral Health Homes at Community Mental Health Provider Settings.工作人员对社区心理健康服务机构实施行为健康家园的障碍和促进因素的看法。
Community Ment Health J. 2022 Aug;58(6):1093-1100. doi: 10.1007/s10597-021-00918-2. Epub 2021 Nov 19.
2
Pre-sentence mental health service use predicts post-sentence mortality in a population cohort of first-time adult offenders.判决前心理健康服务的使用可预测首次成年罪犯人群队列中的判决后死亡率。
Soc Psychiatry Psychiatr Epidemiol. 2015 Jan;50(1):109-24. doi: 10.1007/s00127-014-0919-8. Epub 2014 Jul 1.
3
Feasibility and effectiveness of an automated telehealth intervention to improve illness self-management in people with serious psychiatric and medical disorders.
一种自动化远程医疗干预措施改善严重精神和躯体障碍患者疾病自我管理的可行性和效果。
Psychiatr Rehabil J. 2013 Dec;36(4):297-305. doi: 10.1037/prj0000022.
4
Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review.精神分裂症谱系和双相情感障碍患者中的心血管危险因素在不同种族和民族中的流行情况:文献综述。
Compr Psychiatry. 2014 Feb;55(2):233-47. doi: 10.1016/j.comppsych.2013.09.009. Epub 2013 Oct 22.
5
A case control study of the implementation of change model versus passive dissemination of practice guidelines for compliance in monitoring for metabolic syndrome.代谢综合征监测中实施改变模型与被动传播实践指南对依从性的病例对照研究。
Community Ment Health J. 2013 Apr;49(2):141-9. doi: 10.1007/s10597-011-9472-z. Epub 2012 Feb 16.
6
Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.精神药物的不良内分泌和代谢效应:选择性临床述评。
CNS Drugs. 2009 Dec;23(12):1003-21. doi: 10.2165/11530020-000000000-00000.